TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01565070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biofreeze
Description: Use of Biofreeze ointment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo ointment
Study: NCT01307475

Intervention type: OTHER
Intervention: PTSD Checklist-Specific
Description: Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.

Intervention type: OTHER
Intervention: PTSD Checklist-Specific
Description: Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
Study: NCT04295824

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin imaging and Skin biopsy
Description: Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin imaging and Skin biopsy
Description: Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin imaging and Skin biopsy
Description: Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin imaging and Skin biopsy
Description: Imaging includes:~* Structural Optical Coherence Tomography (OCT) - Skin thickness/roughness.~* Angiographic OCT- Vessel depth/morphology.~* Polarisation-sensitive OCT - Tissue birefringence / collagen index.~* Skin biopsies will be taken from the same volar forearm site as the imaging is performed.
Study: NCT01307475

Intervention type: OTHER
Intervention: PTSD Checklist-Specific
Description: Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.

Intervention type: OTHER
Intervention: Modified Flanagan Quality of Life Scale
Description: Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.

Intervention type: OTHER
Intervention: Modified Flanagan Quality of Life Scale
Description: Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.

Intervention type: OTHER
Intervention: Modified Flanagan Quality of Life Scale
Description: Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.

Intervention type: OTHER
Intervention: Center for Epidemiologic Studies Depression Scale
Description: Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
Study: NCT01008644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline 3%
Description: The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
Study: NCT01307475

Intervention type: OTHER
Intervention: Center for Epidemiologic Studies Depression Scale
Description: Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
Study: NCT01143324

Intervention type: DEVICE
Intervention: MAST™ procedure
Description: Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
Study: NCT03136575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong
Description: a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
Study: NCT01950663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RETeval
Description: RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
Study: NCT03811938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low voltage ablation
Description: Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
Study: NCT00707070

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: efalizumab plus placebo
Description: 1 mg/kg/week subcutaneous for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab plus acitretin
Description: 1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
Study: NCT03132337

Intervention type: OTHER
Intervention: Serial Blood Draws
Description: Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
Study: NCT01509963

Intervention type: OTHER
Intervention: no intervention : measure of score
Description: To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
Study: NCT02777671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: tablets containing gliclazide 80 mg (Diamicron® 80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide
Description: tablets containing gliclazide 80 mg (Diamicron® 80 mg)
Study: NCT03227263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0.9%
Description: 0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
Study: NCT01972750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: daily oral intake of capsule
Study: NCT00004259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCNU 80mg/m2
Description: BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ 200mg/m2
Description: 200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCNU
Description: CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU 150mg/m2
Description: BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU 200mg/m2
Description: BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ 150mg/m2 six 6-week cycles
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ 150mg/m2 six 8-week cycles
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
Study: NCT03134872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed
Study: NCT02765568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise Training
Description: Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
Study: NCT00865826

Intervention type: OTHER
Intervention: Standardized diagnostic evaluation
Description: Participants will undergo a diagnostic evaluation for TB at study entry
Study: NCT04222010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loco-regional anesthesia serratus plane bloc (Ropivacaine 2 mg/mL, 40 mL) and paravertebral placebo bloc (saline, 20 mL)
Description: Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia
Study: NCT00689715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection
Description: A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
Study: NCT04038788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD hf-tRNS
Description: See detail in arm/group descriptions regarding the intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD hf-tRNS
Description: See detail in arm/group descriptions regarding the intervention.
Study: NCT01688154

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2 empty capsules
Study: NCT00368511

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Music Listening
Description: Listen to music and posture measurements
Study: NCT00790907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux background and standard dose UFH
Description: Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein \[GP\] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) \[maximum two additional bolus doses\]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux background and low dose heparin
Description: Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.

Intervention type: DRUG
Group type: OTHER
Intervention: Open label fondaparinux
Description: Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
Study: NCT02022488

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam
Description: Group M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Group M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: Group M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: Group MA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Group MK
Study: NCT04434495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP injection into uterine cavity
Study: NCT03115307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
Study: NCT02666573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fotosan 630, CMS Dental, Copenhagen, Denmark
Description: The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.

Intervention type: OTHER
Group type: OTHER
Intervention: Scaling and root planing
Description: Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
Study: NCT03775421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Description: macitentan 10 mg, film-coated tablet, oral use
Study: NCT00805831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDH
Description: sutureless vascular anastomosis
Study: NCT03410888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Popliteal approach
Description: Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infragluteal approach
Description: Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
Study: NCT02199080

Intervention type: OTHER
Group type: OTHER
Intervention: D-dimer assay before ablation of atrial fibrillation
Description: Blood sample collection for D-dimers measurement
Study: NCT04160507

Intervention type: OTHER
Intervention: Biorepository
Description: To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.

Intervention type: OTHER
Intervention: Biorepository
Description: To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
Study: NCT03166293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive leg training with a physical therapist
Description: Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive leg training with a physical therapist
Description: Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
Study: NCT00446511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo matched to enalapril
Description: Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matched to valsartan
Description: placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matched to valsartan
Description: placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Study: NCT00841685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldlock
Description: Insertion of Goldlock marker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visicoil smallest size
Description: Insertion of Visicoil, smallest size, marker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visicoil larger size
Description: Insertion of Visicoil, larger size, marker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard goldmarker smallest size
Description: Insertion of Bard goldmarker, smallest size

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard goldmarker larger size
Description: Insertion of Bard goldmarker, larger size
Study: NCT03482414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional wooden checkerboard
Description: upper limb training with traditional wooden checkerboard
Study: NCT03811938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation
Description: Catheter ablation aiming for the electrical isolation of the pulmonary veins.
Study: NCT04222010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loco-regional anesthesia : paravertebral bloc (Ropivacaine 4 mg/mL, 20 mL) and serratus plane placebo bloc (saline, 40 mL)
Description: Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loco-regional anesthesia : serratus plane bloc (Ropivacaine 1,3 mg/mL, 40 mL) and paravertebral bloc (Ropivacaine 1,3 mg/mL, 20 mL)
Description: Each patient who underwent thoracoscopic surgery will be assigned to one procedure of Loco-regional anesthesia.
Study: NCT03482414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gaming board with single-player games
Description: upper limb training with a LED-based interactive gaming board equipped with single-player games